Report cover image

Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2027

Publisher MarketsandMarkets
Published Jul 27, 2022
Length 154 Pages
SKU # MKMK17330594

Description

Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2027

The global gene therapy market is valued at an estimated USD 7.3 billion in 2022 and is projected to reach USD 17.2 billion by 2027, at a CAGR of 18.6% during the forecast period. Factors such asrising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth. However,factors like high cost of gene therapy is restraining the growth of this market.

“The cancer segment accounted for the highest growth ratein the gene therapy market, by indication, during the forecast period”

In 2021, cancer segment accounted for the highest growth rate. Growing disease burden of cancer across the globe coupled with rising demand for gene therapies to treat cancer will augment the segmental growth of cancer over the forecast period.

“Asia Pacific: The fastest-growing region in the gene therapy market”

The Asia Pacific market is estimated to record the highest CAGR during the forecast period. The high growth rate of this market can be attributed to the improving healthcare expenditure in emerging economies, increasing product launches, and increasing incidence of cancer and neurological diseases.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1- 32%, Tier 2- 44%, and Tier 3-24%

By Designation: C-level (Managers) - 30%, D-level(CXOs, Directors)- 34%, and Others (Executives) - 36%

By Region: North America -50%, Europe -32%, Asia-Pacific -10%, Rest of the World -8%

List of Companies Profiled in the Report:

Biogen (US)

Sarepta Therapeutics (US)

Gilead Sciences, Inc. (US)

Amgen, Inc. (US)

Novartis AG (Switzerland)

Orchard Therapeutics Plc (UK)

Spark Therapeutics, Inc. (A Part Of ‎F. Hoffmann-La Roche) (US)

AGC Biologics (US)

Anges, Inc. (Japan)

Bluebird Bio, Inc. (US)

Jazz Pharmaceuticals Plc (Ireland)

Dynavax Technologies (US)

Human Stem Cells Institute (Russia)

SibionoGenetech Co., Ltd. (China)

Shanghai Sunway Biotech Co., Ltd. (China)

Uniqure N.V. (Netherland)

Gensight Biologics S.A. (France)

Celgene Corporation (A Bristol-Myers Squibb Company) (US)

Cellectis (France)

Sangamo Therapeutics (US)

Mustang Bio (US)

AGTC (Applied Genetic Technologies Corporation) (US)

Poseida Therapeutics, Inc. (US)

Research Coverage:

This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments such as vectors, indication, delivery method, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges,trends,and opportunities.

Table of Contents

154 Pages
    • STUDY OBJECTIVES
    • MARKET DEFINITION
    • STUDY SCOPE
    • YEARS CONSIDERED
    • CURRENCY CONSIDERED
    • LIMITATIONS
    • STAKEHOLDERS
    • SUMMARY OF CHANGES
    • RESEARCH DATA
    • MARKET SIZE ESTIMATION
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • RESEARCH ASSUMPTIONS
    • RISK ASSESSMENT
  • EXECUTIVE SUMMARY
    • GENE THERAPY MARKET OVERVIEW
    • NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2021)
    • GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET
    • INTRODUCTION
    • MARKET DYNAMICS
    • PRICING ANALYSIS
    • TECHNOLOGY ANALYSIS
    • SUPPLY CHAIN ANALYSIS
    • ECOSYSTEM ANALYSIS OF GENE THERAPY MARKET
    • KEY CONFERENCES AND EVENTS IN 2022–2023
    • REGULATORY ANALYSIS
    • PORTER’S FIVE FORCES ANALYSIS
    • KEY STAKEHOLDERS AND BUYING CRITERIA
    • INTRODUCTION
    • NON-VIRAL VECTORS
    • VIRAL VECTORS
    • INTRODUCTION
    • NEUROLOGICAL DISEASES
    • CANCER
    • DUCHENNE MUSCULAR DYSTROPHY
    • HEPATOLOGICAL DISEASES
    • OTHER INDICATIONS
    • INTRODUCTION
    • IN VIVO GENE THERAPY
    • EX VIVO GENE THERAPY
    • INTRODUCTION
    • NORTH AMERICA
    • EUROPE
    • ASIA PACIFIC
    • REST OF THE WORLD
    • OVERVIEW
    • MARKET SHARE ANALYSIS, 2021
    • REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • COMPANY EVALUATION QUADRANT
    • COMPANY FOOTPRINT ANALYSIS
    • COMPETITIVE SCENARIO
    • BIOGEN
    • SAREPTA THERAPEUTICS
    • GILEAD SCIENCES, INC.
    • AMGEN, INC.
    • NOVARTIS AG
    • ORCHARD THERAPEUTICS PLC
    • SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY)
    • AGC BIOLOGICS
    • ANGES, INC.
    • BLUEBIRD BIO, INC.
    • JAZZ PHARMACEUTICALS PLC
    • DYNAVAX TECHNOLOGIES
    • HUMAN STEM CELLS INSTITUTE
    • SIBIONO GENETECH CO., LTD.
    • SHANGHAI SUNWAY BIOTECH CO., LTD.
    • UNIQURE N.V.
    • GENSIGHT BIOLOGICS S.A.
    • CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
    • CELLECTIS
    • SANGAMO THERAPEUTICS
    • MUSTANG BIO
    • AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
    • POSEIDA THERAPEUTICS, INC.
    • DISCUSSION GUIDE
    • KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
    • AVAILABLE CUSTOMIZATION OPTIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us